Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Operating Leases (2019 - 2025)

Historic Operating Leases for Spero Therapeutics (SPRO) over the last 7 years, with Q3 2025 value amounting to $1.5 million.

  • Spero Therapeutics' Operating Leases fell 4963.58% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year decrease of 4963.58%. This contributed to the annual value of $2.6 million for FY2024, which is 3330.72% down from last year.
  • Spero Therapeutics' Operating Leases amounted to $1.5 million in Q3 2025, which was down 4963.58% from $1.8 million recorded in Q2 2025.
  • In the past 5 years, Spero Therapeutics' Operating Leases registered a high of $6.7 million during Q1 2021, and its lowest value of $1.5 million during Q3 2025.
  • Moreover, its 5-year median value for Operating Leases was $4.4 million (2023), whereas its average is $4.3 million.
  • Its Operating Leases has fluctuated over the past 5 years, first surged by 4737.89% in 2021, then tumbled by 4963.58% in 2025.
  • Over the past 5 years, Spero Therapeutics' Operating Leases (Quarter) stood at $6.0 million in 2021, then decreased by 17.01% to $5.0 million in 2022, then decreased by 22.84% to $3.8 million in 2023, then plummeted by 33.31% to $2.6 million in 2024, then crashed by 43.08% to $1.5 million in 2025.
  • Its last three reported values are $1.5 million in Q3 2025, $1.8 million for Q2 2025, and $2.2 million during Q1 2025.